Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Sell
8
MLEC Quote, Financials, Valuation and Earnings
Last price:
$0.59
Seasonality move
:
-12.86%
Day range:
$0.56 - $0.62
52-week range:
$0.53 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.92x
P/B ratio:
3.77x
Volume:
7.4K
Avg. volume:
23.8K
1-year change:
-58.21%
Market cap:
$21.5M
Revenue:
$5.6M
EPS (TTM):
-$0.20
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Moolec Science SA has 435.71% upside to fair value with a price target of -- per share.
MLEC vs. S&P 500
-
Over the past 5 trading days, Moolec Science SA has underperformed the S&P 500 by -23.04% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Moolec Science SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moolec Science SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Moolec Science SA reported revenues of $1.5M.
Earnings Growth
-
Moolec Science SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Moolec Science SA reported earnings per share of -$0.07.
Enterprise value:
39.6M
EV / Invested capital:
--
Price / LTM sales:
3.92x
EV / EBIT:
--
EV / Revenue:
7.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$472.6K
Return On Assets:
-28.43%
Net Income Margin (TTM):
-129.99%
Return On Equity:
-93.42%
Return On Invested Capital:
-45.87%
Operating Margin:
-193.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $5.4M | $1.7M | $1.6M | |
| Gross Profit | -- | $77.1K | $266.9K | $220.4K | $14.8K | |
| Operating Income | -- | -$50.9M | -$8.9M | -$2.3M | -$2.1M | |
| EBITDA | -- | -$52.5M | -$5.7M | -$1.5M | -$1.1M | |
| Diluted EPS | -- | -$1.36 | -$0.21 | -$0.04 | -$0.05 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $3.2M | $11.2M | |
| Total Assets | -- | -- | -- | $22.5M | $32.6M | |
| Current Liabilities | -- | -- | -- | $12.5M | $7.4M | |
| Total Liabilities | -- | -- | -- | $13.6M | $26.9M | |
| Total Equity | -- | -- | -- | $8.9M | $5.7M | |
| Total Debt | -- | -- | -- | $2.4M | $21.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$9.3M | -$8.7M | -$1.7M | -$1.1M | |
| Cash From Investing | -- | -$2.2M | -$99.4K | $174.6K | -$59.7K | |
| Cash From Financing | -- | $11.2M | $11.3M | -$127.4K | -$542.4K | |
| Free Cash Flow | -- | -$9.5M | -$8.8M | -$1.8M | -$1.2M | |
MLEC
Sector
Market Cap
$21.5M
$264.2M
Price % of 52-Week High
17.23%
73.33%
Dividend Yield
0%
0%
Shareholder Yield
--
3.01%
1-Year Price Total Return
-58.21%
-13.26%
Beta (5-Year)
--
0.413
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.64
200-day SMA
Sell
Level
$0.87
Bollinger Bands (100)
Sell
Level
0.71 - 0.89
Chaikin Money Flow
Sell
Level
-48.7M
20-day SMA
Sell
Level
$0.74
Relative Strength Index (RSI14)
Sell
Level
35.20
ADX Line
Sell
Level
15.42
Williams %R
Buy
Level
-98.6581
50-day SMA
Sell
Level
$0.73
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
101.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0771)
Sell
CA Score
(Annual)
Level (-2.4682)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (7.9213)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company’s revenues arise from operations in Argentina.
Stock Forecast FAQ
In the current month, MLEC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MLEC average analyst price target in the past 3 months is --.
-
Where Will Moolec Science SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moolec Science SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Moolec Science SA?
Analysts are divided on their view about Moolec Science SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moolec Science SA is a Sell and believe this share price will drop from its current level to --.
-
What Is Moolec Science SA's Price Target?
The price target for Moolec Science SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MLEC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moolec Science SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MLEC?
You can purchase shares of Moolec Science SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moolec Science SA shares.
-
What Is The Moolec Science SA Share Price Today?
Moolec Science SA was last trading at $0.59 per share. This represents the most recent stock quote for Moolec Science SA. Yesterday, Moolec Science SA closed at $0.56 per share.
-
How To Buy Moolec Science SA Stock Online?
In order to purchase Moolec Science SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
